Skip to main content
SpringerLink
Log in

Hemmstoffe des Renin-Angiotensin-Systems

  • Chapter
Arzneiverordnungs-Report 2015

Zusammenfassung

Hemmstoffe des Renin-Angiotensin-Systems (RAS) gehören zu den erfolgreichsten Arzneimitteln zur Behandlung von Hypertonie, Herz- und Nierenkrankheiten. Angiotensinrezeptorantagonisten gewinnen nach Auslaufen des Patentschutzes mehrerer Sartane weitere Marktanteile. Dagegen verliert erneut deutlich der bisher einzige Renininhibitor Aliskiren und sinkt auf 0,35% der Gesamtgruppe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, Reid CM, Golledge J, Kingwell BA (2013): Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 309: 453–460

    Article  CAS  PubMed  Google Scholar 

  • Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010): The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25: 3977–3982

    Article  CAS  PubMed  Google Scholar 

  • Anlauf M (2006): Beurteilung von Therapien mit der „number needed to treat“ Dtsch Ärztebl 103: A3254–A3258

    Google Scholar 

  • Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM (2013): Comparative effec- tiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. Cmaj 185: 1035–1041

    Article  PubMed Central  PubMed  Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdf

  • Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L,

    Google Scholar 

  • Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators (2010): Renal out-comes with diff erent fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375: 1173–1181

    Article  PubMed  Google Scholar 

  • Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH (2011a): Antihypertensive drugs and risk of cancer: network me- ta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 12: 65–82

    Article  CAS  PubMed  Google Scholar 

  • Bangalore S, Kumar S, Wetterslev J, Messerli FH (2011b): Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 342:d2234. doi: 10.1136

    PubMed Central  PubMed  Google Scholar 

  • Bangalore S, Kumar S, Messerli FH (2012): When Conventional Heart Failure Therapy is not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist? Congest Heart Fail. doi: 10.1111/chf.12011

    Google Scholar 

  • Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group (2004): Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952–1961

    Article  CAS  PubMed  Google Scholar 

  • Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K (2015): Role of neprilysin inhibitor combi- nations in hypertension: insights from hypertension and heart failure trials. Eur Heart J doi:10.1093/eurheartj/ehv142

    Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group (2008): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898

    Article  Google Scholar 

  • Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extre- mera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group (2012): Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344: 1–10

    Google Scholar 

  • Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L (2012): Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 344:e269–7

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists' Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists' Collaboration (2007): Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951–958

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists' Collaboration (2015): Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet 385: 867–874

    Article  Google Scholar 

  • Brown MJ (2008): Aliskiren. Circulation 118: 773–784

    Article  CAS  PubMed  Google Scholar 

  • Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2011): Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter 1. Auflage Version 1.3

    Google Scholar 

  • Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators (2009): Supramaximal dose of candesartan in protein- uric renal disease. J Am Soc Nephrol. 20: 893–900

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Carey RM (2013): Newly discovered components and actions of the renin-angiotensin system. Hypertension 62: 818–822

    Article  CAS  PubMed  Google Scholar 

  • Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005): Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026–2033

    Article  CAS  PubMed  Google Scholar 

  • Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS (2014): Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardio- vasc Diabetol 13: 9–1

    Google Scholar 

  • Cheng J, Zhang W, Zhang X, et al (2014): Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 174:773–785.

    Article  CAS  PubMed  Google Scholar 

  • Carter BL, Chrischilles EA, Rosenthal G, Gryzlak BM, Eisenstein EL, Vander Weg MW (2014): Efficacy and safety of nighttime dosing of antihypertensives: review of the Literature and design of a pragmatic clinical trial. J Clin Hypertens (Greenwich) 16: 115–121

    Article  CAS  Google Scholar 

  • Cleland JG, Tendera M, Adamus J, Freemantle, Polonski L, Taylor J; PEP-CHF Investigators (2006): The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 27: 2338–2345

    Article  CAS  PubMed  Google Scholar 

  • Coats AJ (2002): Omapatrilat - the story of Overture and Octave. Int J Cardiol 86:1–4.

    Article  PubMed  Google Scholar 

  • Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators (2001): A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675

    Article  CAS  PubMed  Google Scholar 

  • Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B (2011): The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: metaanalysis of randomized trials. J Hypertens 29: 4–16

    Article  CAS  PubMed  Google Scholar 

  • Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kris- tiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group (2002): Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003

    Article  Google Scholar 

  • Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360: 752–760

    Google Scholar 

  • Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207

    Article  CAS  PubMed  Google Scholar 

  • Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A.( 2015): Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. Jama 313:603–615

    Google Scholar 

  • European Medicines Agency (2014): PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system. Press Release April 11,2014; EMA/196502/>201–4

    Google Scholar 

  • FDA Drug Safety Communication (2013): FDA approves label changes to include intestinal Problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medo- xomil. 7-3–2013

    Google Scholar 

  • FDA. (2014): http://www.medscape.com/viewarticle/837303

  • Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E (2000): Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355:1575–1581

    Article  CAS  PubMed  Google Scholar 

  • Fralick M, Macdonald EM, Gomes T, et al (2014): Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 349:g6196.

    Google Scholar 

  • Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P (2013): Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–1903

    Article  CAS  PubMed  Google Scholar 

  • Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX (2013): Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 310: 2544–2553

    Article  CAS  PubMed  Google Scholar 

  • Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M (2014): Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet 383: 1889–1898

    Article  CAS  PubMed  Google Scholar 

  • GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G (2009): Valsartan for prevention of recurrent atrial fibril- lation. N Engl J Med 360: 1606–1617

    Google Scholar 

  • Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA,

    Google Scholar 

  • Swedberg K;CHARM Investigators and (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angio- tensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772–776

    Article  PubMed  Google Scholar 

  • Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators (2011): Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364: 907–917

    Article  CAS  PubMed  Google Scholar 

  • Hasenfuss G, Edelmann F, Wachter R (2013): Empfehlung zur Herzinsuffizienz Was gibt es Neues? Internist 54: 1141–1151

    Article  CAS  PubMed  Google Scholar 

  • Heerspink HL, de Zeeuw D (2010): Composite renal endpoints: was ACCOMPLISH accom- plished? Lancet 375: 1140–1142

    Article  PubMed  Google Scholar 

  • Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, Cooper M, Grobbee DE, Mancia G, Mogensen CE, Neal B, Chalmers J; ADVANCE Collaborative Group (2010): Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31: 2888–2896

    Article  Google Scholar 

  • Hermida RC, Ayala DE, Mojon A, Fernandez JR (2011a): Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 22: 2313–2321

    Article  PubMed Central  PubMed  Google Scholar 

  • Hermida RC, Ayala DE, Mojon A, Fernandez JR (2011b): Influence of time of day of blood pres- sure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34: 1270–1276

    Article  PubMed Central  PubMed  Google Scholar 

  • Hsu TW, Liu JS, Hung SC, et al (2014): Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 174: 347–354

    Article  PubMed  Google Scholar 

  • Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D (2014): Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J 167: 160168 e–1

    Google Scholar 

  • Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H; ORIENT study investigators (2011): Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54: 2978–2986

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B et al ACCOMPLISH Trial Investigators (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359: 2417–2428

    Google Scholar 

  • Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA (2011): Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 57: 174–179

    Article  CAS  PubMed  Google Scholar 

  • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group (2004): Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsar- tan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031

    Article  Google Scholar 

  • Julius S, Nesbitt SD, Egan BM. for the Trial of Preventing Hypertension (TROPHY) Study Investi- gators (2006): Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 354: 1685–1697

    Article  CAS  PubMed  Google Scholar 

  • Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H (2009): Angiotensin II receptor blocker-based vs. nonangiotensin II receptor blocker-based therapy in patients with angiographically docu- mented coronary artery disease and hypertension: the Heart Institute of Japan Candesar- tan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 30: 1203–1212

    Article  CAS  PubMed  Google Scholar 

  • Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators (2009): Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374: 1840–1848

    Article  CAS  PubMed  Google Scholar 

  • Kunz R, Friedrich C, Wolbers M, Mann JFE (2008): Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30–48

    Article  PubMed  Google Scholar 

  • Lakhdar R, Al-Mallah MH, Lanfear DE (2008): Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14: 181–188

    Article  CAS  PubMed  Google Scholar 

  • Laverman GD, Navis G, Henning RH, de Jong D, de Zeeuw D (2002): Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020–1025

    Article  CAS  PubMed  Google Scholar 

  • Levy BI (2004): Can angiotensin II Type 2 receptors have deleterious effects in cardiovascular disease? Circulation 109: 8–13

    Article  PubMed  Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group (1993): The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462

    Article  CAS  PubMed  Google Scholar 

  • Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al for the SCOPE Study Group

    Google Scholar 

  • : The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875–886

    Google Scholar 

  • Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO study group (2008): The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487–1496

    Article  Google Scholar 

  • Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW (2010): Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 15:195–204

    Article  PubMed  Google Scholar 

  • Lv J, Ehteshami P Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V (2013): Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185: 949–957

    Article  PubMed Central  PubMed  Google Scholar 

  • Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH (2013): Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials BMJ Jan 28;346:f360. doi: 10.1136

    Google Scholar 

  • Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduc- tion and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26: 855–865

    Google Scholar 

  • Mann JFE, Schmieder RE, McQueen M, Dyal L et al on behalf of the ONTARGET investigators (2008): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553

    Google Scholar 

  • Mann JFE, Schmieder RE, Dyal L, McQueen MJ et al (2009): Effect of telmisartan on renal out- comes: a randomized trial. Ann Intern Med 151: 1-10, W1–2

    Google Scholar 

  • Marott SC, Nielsen SF, Benn M, Nordestgaard BG (2014): Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 35: 1205–1214

    Article  CAS  PubMed  Google Scholar 

  • Maschio G, Albert D, Ganin G, Locatelli F, Mann JFE et al (1996): Effect of the angiotensin-con- verting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939–945

    Article  CAS  PubMed  Google Scholar 

  • Massie BM, Carson PE, McMurray JJ, Komajda M, et al I-PRESERVE Investigators (2008): Irbesar- tan in patients with heart failure and preserved ejection fraction. N Engl J Med. 359: 2456246–7.

    Google Scholar 

  • McMurray JJ, Östergren J, Swedberg K, Granger CB, Held P, Eric L Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, for the CHARM Investigators and Committees (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767–771

    Article  CAS  PubMed  Google Scholar 

  • Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000): Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. Brit Med J 321: 1440–1444

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • National Collaborating Centre for Chronic Conditions (2006): Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians. Internet: http://guidance.nice. org.uk/CG34/guidance/pdf/English Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M,

    Google Scholar 

  • Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE (2013): Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 310: 1135–1144

    Article  PubMed  Google Scholar 

  • Oghlakian GO, Sipahi I, Fang JC (2011): Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc 86: 531–539

    Article  PubMed Central  PubMed  Google Scholar 

  • Padwal R, Lin M, Etminan M, Eurich DT (2014): Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 63: 977–983

    Article  CAS  PubMed  Google Scholar 

  • Palmer SC, Mavridis D, Navarese E, et al (2015) Comparative efficacy and safety of blood pres- sure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet385: 2047–2056

    Google Scholar 

  • Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators (2008): Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433–2446

    Article  CAS  PubMed  Google Scholar 

  • Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators (2012): Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204–2213

    Article  CAS  PubMed  Google Scholar 

  • Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swed- berg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators.(2003a): Valsar- tan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906

    Article  CAS  PubMed  Google Scholar 

  • Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees (2003b): Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 759–766

    Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000): Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587

    Article  CAS  PubMed  Google Scholar 

  • Pitt B (2004): ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in PEACE? N Engl J Med 351: 2115–2117

    Article  CAS  PubMed  Google Scholar 

  • Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, Komajda M, Kuskowski M, Massie BM; I-PRESERVE Trial Investigators (2012): Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail 5: 217–225

    Article  CAS  PubMed  Google Scholar 

  • Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA (2012):

    Google Scholar 

  • Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87: 732–738

    Google Scholar 

  • Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F,

    Google Scholar 

  • Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologie Diabetes Complications Trial (BENEDICT) Investigators (2004): Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941–1951

    Article  PubMed  Google Scholar 

  • Sakata Y, Shiba N, Takahashi J, et al (2015): Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J 36:915–923

    Article  PubMed Central  PubMed  Google Scholar 

  • Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Lüders S, Murray GD, Richter PS, Roine RO, Terent A, Thijs V, Berge E; SCAST Study Group (2011): The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377: 741–750

    Article  Google Scholar 

  • Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005): Additional antiprotein- uric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 16: 3038–3045

    Article  CAS  PubMed  Google Scholar 

  • Schmieder RE, Hilgers KF, Schlaich MP, Schmidt MW (2007): Renin angiotensin system and cardiovascular risk. Lancet 369: 1208–1219

    Article  CAS  PubMed  Google Scholar 

  • Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010): Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 55: 2299–2307

    Article  PubMed  Google Scholar 

  • Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group (2003): The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 234: 1699–703

    Article  Google Scholar 

  • Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P,

    Google Scholar 

  • Diener HC; MOSES Study Group (2005): Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218–1226

    Article  Google Scholar 

  • Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010): Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11: 627–636

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Staessen JA, Li Y, Thijs L, Wang JG (2005): Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 28: 385–407

    Article  PubMed  Google Scholar 

  • Staessen JA, Richart T, Wang Z, Thijs L (2010): Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. Hypertension 55: 819–831

    Article  CAS  PubMed  Google Scholar 

  • Svensson P, de Faire U, Sleight P, Yusuf S, Jan Östergren J (2001): Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38: e28–e32

    Article  PubMed  Google Scholar 

  • The ACTIVE I Investigators: Irbesartan in patients with atrial fibrillation. N Engl J Med 364: 928–938

    Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997

    Article  Google Scholar 

  • The DREAM Trial Investigators (2006): Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551–1562

    Article  Google Scholar 

  • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003): Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, place- bo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782–788

    Article  Google Scholar 

  • The GISEN Group (1997): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863

    Article  Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000): Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153

    Article  Google Scholar 

  • The Indian Polycap Study (TIPS) (2009): Effects of a polypill (Polycap) on risk factors in mid- dle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373: 1341–1351

    Article  Google Scholar 

  • The ONTARGET Investigators (2008): Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559

    Article  Google Scholar 

  • The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008): Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174–1183

    Article  Google Scholar 

  • Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. (2011): Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305: 913–922

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E (2012): Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 33: 2088–2097

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Verma S, Strauss M (2004): Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction - and patients may need to be told. BMJ 329: 1248124–9

    Article  Google Scholar 

  • Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB (2005a): Cardio- vascular morbidity and mortality in hypertensive patients with a history of atrial fibrilla- tion: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45: 705–711

    Article  PubMed  Google Scholar 

  • Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005b): Angiotensin II receptor blockade reduc- es new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45: 712–719

    Article  CAS  PubMed  Google Scholar 

  • Walker AM, Liang C, Clifford CR, Parker C, Feldman A (2014): Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors. Pharmacoepidemiol Drug Saf 23: 348–356

    Article  CAS  PubMed  Google Scholar 

  • Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013): Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 381: 537–545

    Article  PubMed  Google Scholar 

  • White HD (2003): Commentary. Candesartan and heart failure: the allure of CHARM. Lancet 362: 754–755

    Article  PubMed  Google Scholar 

  • Wing LM, Reid MC, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592

    Article  CAS  PubMed  Google Scholar 

  • Yusuf S (2002): From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89 (2A): 18A-25A Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees (2003): Effects of candesartan in pa- tients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777–781

    Article  Google Scholar 

  • Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S for the PRoFESS Study Group (2008): Telmis- artan to prevent recurrent stroke and cardiovascular Events. N Engl J Med 359: 1225–1237

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franz Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Anlauf, M., Weber, F. (2015). Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_4

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_4

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation